Therapy (HCV)

Multicenter Study Finds Consensus Interferon Superior

Published in Hepatitis Weekly, October 27th, 1997

A synthetic interferon may be more effective than standard interferon therapy in the treatment chronic hepatitis C virus, according to a multicenter study group.

The Consensus Interferon Study Group found a treatment protocol of 9 (mu)g synthetic interferon three times weekly for six months to be safe and effective in reducing serum hepatitis C virus (HCV) RNA concentrations.

Consensus interferon (CIFN) (Amgen Inc., Thousand Oaks, California) is a non-natural, synthetic, recombinant type-1 interferon derived by aligning the sequences of the known interferon alpha (IFN-(alpha)) nonallelic subtypes, and assigning the most commonly observed amino acid...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1997-10-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry